Isotopia Molecular Imaging and Seibersdorf Labor have entered into an agreement for the production of no-carrier-added Lutetium-177, a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for the treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.
Seibersdorf
Labor, a GMP Contract manufacturing of radiopharmaceuticals, engaged in the
development, production, and commercialization of radiopharmaceuticals, will
produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for
distribution in Europe.
Isotopia
Molecular Imaging and Seibersdorf Labor intend to expand their partnership to
include commercial-scale production of 177Lu n.c.a and labeling services to
meet future commercial market demand. In addition, both companies have also
committed themselves to collaborating on the development of GMP manufacturing processes
for other emerging medical isotopes.
To
read more please visit:
Isotopia
Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for
177Lu n.c.a.